Sarepta Therapeutics (SRPT) Tops Q4 EPS by 23c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($1.24), $0.23 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $258.4 million versus the consensus estimate of $250.4 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist